EMIT-AF/VTE

Edoxaban management in diagnostic and therapeutic procedures

17/02/2017 to 31/05/2019

Edoxaban has been approved in 2015 by the European Medicines Agency (EMA) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack (TIA) as well as for the treatment of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and prevention of recurrent VTE in adults.
Patients receiving Non-VKA Oral Anticoagulants (NOACs) undergo diagnostic and thearpeutic procedures at a rate of 10%/yeari. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without heparin bridging. There is only minimal information on the peri-procedural usage pattern of edoxaban and the related outcome data currently available. Therefore, further real-world clinical data on the periprocedural usage pattern of edoxaban in the context of any diagnostic or interventional procedure in patients with NVAF or VTE will be collected in this registry.